Eden Biologics   Report issue

For profit Phase 1 Phase 3
Founded: Hsinchu Taiwan (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2017
NCT03161457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

JHL Biotech, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

rituximab (rituxan) (3 trials)

Drugs in Phase 1 Trials (2)

bevacizumab (avastin) (1 trial)

dornase alfa (pulmozyme) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3